Document is current
Any future updates will be listed below
-
Authors
Brand, Judith S. https://orcid.org/0000-0002-3720-1274
Gauffin, Oskar https://orcid.org/0000-0003-1593-356X
Sartori, Daniele https://orcid.org/0000-0003-3634-0317
Fusaroli, Michele https://orcid.org/0000-0002-0254-2212
Sköld, Helena
Bergvall, Tomas https://orcid.org/0000-0003-4394-3431
Sandberg, Lovisa https://orcid.org/0000-0001-6982-5244
Wallberg, Magnus https://orcid.org/0009-0003-2681-2226
Hjelmström, Peter https://orcid.org/0000-0001-6422-284X
Norén, G. Niklas https://orcid.org/0000-0002-4595-230X
- License Information
-
More Information
Article History
Received: 12 September 2025
Accepted: 9 December 2025
First Online: 30 January 2026
Declarations
:
: JSB, OG, DS, MF, HS, TB, LS, MW, and PH have no conflict of interest to declare. GNN is an Editorial Board member of Drug Safety . GNN was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: The data that support the findings of this study are not publicly available. Access to the data is restricted based on the conditions for access within the WHO Programme for International Drug Monitoring. Subject to these conditions, data are available from the authors on reasonable request. For further inquiries, please contact Uppsala Monitoring Centre via .
: Not applicable.
: Not applicable.
: JSB, OG, DS, and GNN were responsible for the conceptualisation of this work. JSB performed the formal analysis of the data. All authors participated in interpreting the results from the data. JSB drafted the manuscript with support from OG, DS and GNN. All authors reviewed and edited the manuscript and approved the final version for submission.
: Not applicable.
: The code used to analyse the reports from VigiBase will be made available on reasonable request.
